U.S. FDA approves Biogen's multiple sclerosis drug, Tecfidera
March 27 (Reuters) - U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
Combined clinical trial data showed Tecfidera, formerly known as BG-12, cut the average relapse rate by 49 percent after two years compared to patients taking a placebo.
- Police hunt for motive as search for Malaysian jet spans hemispheres |
- Russia media say Crimea votes 93 percent to quit Ukraine |
- Ukraine, Russia agree Crimea truce until March 21-Ukraine minister
- Malaysian PM says lost airliner was diverted deliberately |
- Democrats seek ways to limit Obamacare fallout after Florida defeat